Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flonoltinib maleate - Chengdu Zenitar Biomedical Technology

Next Previous
Drug Profile

Flonoltinib maleate - Chengdu Zenitar Biomedical Technology

Alternative Names: Flonoltinib; Flonoltinib - Chengdu Zenitar Biomedical Technology; Flunotinib; Flunotinib - Chengdu Zenitar Biomedical Technology

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Zenitar Biomedical Technology
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelofibrosis; Polycythaemia vera
  • Clinical Phase Unknown COVID 2019 infections
  • Preclinical Haemophagocytic lymphohistiocytosis

Most Recent Events

  • 23 Sep 2025 Phase-II clinical trials in Polycythaemia vera (Second-line therapy or greater) in China (PO) (NCT07232290)
  • 19 Mar 2025 Chengdu Zenitar Biomedical Technology completes phase I clinical trials in Myelofibrosis in China (PO) (NCT05153343)
  • 19 Mar 2025 Chengdu Zenitar Biomedical Technology completes phase-I clinical trials in Myeloproliferative disorders in China (PO) (NCT05153343)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top